Nissay Asset Management Corp Bei Gene, Ltd. Transaction History

Nissay Asset Management Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $919,764 - $1.32 Million	-4,156 Closed	0 $0
Q3 2020 Oct 20, 2020	BUY	$189.18 - $286.44 $43,700 - $66,167	231 Added 5.89%	4,156 $1.19 Million
Q2 2020 Jul 27, 2020	BUY	$123.9 - $195.41 $73,472 - $115,878	593 Added 17.8%	3,925 $739,000
Q1 2020 May 05, 2020	BUY	$121.84 - $173.19 $51,416 - $73,086	422 Added 14.5%	3,332 $410,000
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $17,714 - $31,876	-153 Reduced 5.0%	2,910 $482,000
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $19,418 - $23,874	161 Added 5.55%	3,063 $375,000
Q2 2019 Aug 07, 2019	BUY	$113.99 - $146.86 $16,984 - $21,882	149 Added 5.41%	2,902 $360,000
Q1 2019 May 03, 2019	BUY	$122.82 - $151.83 $15,598 - $19,282	127 Added 4.84%	2,753 $363,000
Q4 2018 Feb 06, 2019	BUY	$107.01 - $175.15 $281,008 - $459,943	2,626 New	2,626 $368,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.